Jpmorgan Chase & CO Zentalis Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 746,476 shares of ZNTL stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

746,476

Previous 859,710 13.17%

Holding current value

$1.15 Million

Previous $2.6 Million 54.45%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$1.59 - $3.24 $180,042 - $366,878	-113,234 Reduced 13.17%	746,476 $1.19 Million
Q4 2024 Feb 12, 2025	BUY	$2.7 - $4.03 $1 Million - $1.49 Million	370,511 Added 75.74%	859,710 $2.6 Million
Q3 2024 Dec 26, 2024	SELL	$2.9 - $4.57 $19,171 - $30,212	-6,611 Reduced 1.33%	489,199 $1.8 Million
Q3 2024 Nov 08, 2024	SELL	$2.9 - $4.57 $19,171 - $30,212	-6,611 Reduced 1.33%	489,199 $1.8 Million
Q2 2024 Dec 26, 2024	BUY	$4.09 - $16.13 $27,038 - $106,635	6,611 Added 1.35%	495,810 $2.03 Million
Q2 2024 Aug 12, 2024	BUY	$4.09 - $16.13 $1.79 Million - $7.05 Million	437,189 Added 745.79%	495,810 $2.03 Million
Q1 2024 Dec 26, 2024	SELL	$10.83 - $16.49 $4.66 Million - $7.1 Million	-430,578 Reduced 88.02%	58,621 $923,000
Q1 2024 May 10, 2024	SELL	$10.83 - $16.49 $377,176 - $574,297	-34,827 Reduced 37.27%	58,621 $923,000
Q4 2023 Dec 26, 2024	SELL	$9.84 - $20.13 $3.89 Million - $7.97 Million	-395,751 Reduced 80.9%	93,448 $1.42 Million
Q4 2023 Feb 12, 2024	SELL	$9.84 - $20.13 $83,453 - $170,722	-8,481 Reduced 8.32%	93,448 $1.42 Million
Q3 2023 Nov 14, 2023	SELL	$19.63 - $28.29 $172,037 - $247,933	-8,764 Reduced 7.92%	101,929 $2.04 Million
Q2 2023 Aug 11, 2023	BUY	$17.41 - $30.05 $872,101 - $1.51 Million	50,092 Added 82.66%	110,693 $3.12 Million
Q1 2023 May 18, 2023	BUY	$16.14 - $24.94 $927,840 - $1.43 Million	57,487 Added 1846.08%	60,601 $1.04 Million
Q1 2023 May 11, 2023	SELL	$16.14 - $24.94 $705,673 - $1.09 Million	-43,722 Reduced 93.35%	3,114 $53,000
Q4 2022 Feb 13, 2023	BUY	$18.07 - $25.6 $82,146 - $116,377	4,546 Added 10.75%	46,836 $943,000
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $291,514 - $457,229	-14,410 Reduced 25.41%	42,290 $916,000
Q2 2022 Aug 11, 2022	SELL	$17.91 - $52.25 $875,422 - $2.55 Million	-48,879 Reduced 46.3%	56,700 $1.59 Million
Q1 2022 May 11, 2022	BUY	$41.58 - $80.89 $3.25 Million - $6.32 Million	78,102 Added 284.25%	105,579 $4.87 Million
Q4 2021 Feb 10, 2022	BUY	$66.92 - $84.79 $161,946 - $205,191	2,420 Added 9.66%	27,477 $2.31 Million
Q3 2021 Nov 12, 2021	BUY	$46.83 - $73.5 $1.17 Million - $1.84 Million	25,057 New	25,057 $1.67 Million

Others Institutions Holding ZNTL

# of Institutions

124

Shares Held

60.6M

Call Options Held

Put Options Held

22K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $87.8M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Zentalis Pharmaceuticals, Inc. Transaction History